After meeting with pharma lobbyists, Trump drops promise

New Post Public Reply Private Reply Replies (0) Message Board

Jan 31, 2017 at 12:20 PM 280

Quote:

After meeting with pharma lobbyists, Trump drops promise to negotiate drug prices

The new plan is tax cuts and deregulation.

Updated by Matthew Yglesias@mattyglesiasmatt@vox.com Jan 31, 2017, 11:50am EST

A lot happened in the 2016 campaign, but one of the things Donald Trump did to win the election was shift to the left on a number of key issues — promising to avoid cuts in Social Security and Medicare benefits and adopting a longstanding Democratic pledge to let Medicare negotiate bulk discounts in the price it pays for prescription drugs.

Today, after a meeting with pharmaceutical industry lobbyists and executives, he abandoned that pledge, referring to an idea he supported as recently as three weeks ago as a form of “price fixing” that would hurt “smaller, younger companies.” Instead of getting tough, Trump’s new plan is that he’s “going to be lowering taxes” and “getting rid of regulations.”

New drugs are generally covered by patent monopolies, so drug companies have a lot of pricing power; other companies can’t produce the same drug without paying royalties, so there’s little competition.

But most countries use their nationalized health care systems to negotiate a good deal on drug prices. Manufacturing pills is cheap, so it’s usually still profitable for a company to sell medicine at a pretty steep discount.

The United States doesn’t have a nationalized health care system, but we do have Medicare for senior citizens, and since the USA is a very large country, that’s still a huge potential bulk purchaser. But a 2003 law written by congressional Republicans and signed by George W. Bush prohibits the federal government from using that negotiating power.

As recently as January 11, President-elect Trump was promising to revisit this policy.

“Pharma has a lot of lobbies, a lot of lobbyists and a lot of power. And there’s very little bidding on drugs,” he said at a press conference at Trump Tower in Manhattan. “We’re the largest buyer of drugs in the world, and yet we don’t bid properly.”

Today he apparently changed his mind. According to Herb Jackson, the designated pool reporter for the day, Trump’s new policy on prescription drugs is that drug companies should get tax cuts and deregulation (emphasis added):

I'll oppose anything that makes it harder for smaller, younger companies to take the risk of bringing their product to a vibrantly competitive market. That includes price-fixing by the biggest dog in the market, Medicare, which is what's happening. But we can increase competition and bidding wars, big time.

So what I want, we have to get lower prices, we have to get even better innovation and I want you to move your companies back into the United States. And I want you to manufacture in the United States. We're going to be lowering taxes, we're going to be getting rid of regulations that are unnecessary.

Many people watching the chaotic rollout of Trump’s executive orders on immigration, his demands for investigations into phantom vote rigging, his mysterious ties to Russia, his financial conflicts of interest, and his bizarre lies about Inauguration Day crowd size have found themselves wondering why more Republicans don’t stand up to him.

This event with PhRMA lobbyists explains why. On most of the big public policy issues of the day, Trump is a very conventional Republican. And on those issues where he hasn’t been conventional, Republican Congress members and business executives feel confident they can turn him around.

On some issues, they probably won’t. But on this issue, they just did.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Decoy Wines Bolsters Emmy Partnership with Creative Grant

Popping Corks for Creativity: Decoy's New Chapter Stepping outside the vines and into the artistic limelight, Decoy Wines is shaking up the status quo. Announcing the launch of the Pour to What's Possible Grant, the brand is throwing down $10,000 to back creatives itching to make waves in entertainment. Now, doesn't that stand out? The Grit Behind the Grapes: Decoy's...

TETRA Technologies to Engage at Key Investor Events

Revving Up for Major Investor Conferences All eyes are on TETRA Technologies Inc. (NYSE:TTI) as they gear up to make splashy appearances at not one, but two high-profile investor conferences in New York. It's setting the stage for some potentially juicy conversations about where TTI, a player with deep roots in energy services, is heading in this whirlwind of an industry....

Scienjoy's Strategic Stake in Education: Bold Move?

Testing the Waters with Education Stake Talk about mixing oil and water. Scienjoy Holding Corporation, those tech-savvy folks from China's live streaming circles, have set their sights on education with a hefty 29.9% stake in Leader Education Limited. For HK$102.69 million, that’s about US$13.1 million, they’re jumping into an industry with a different flavor....

PLAY Palm Angels Launches at Pacsun with Avani Gregg

Revamping Streetwear with PLAY Palm Angels and Pacsun In a move that's making waves from the fashion runways straight into the heart of youth culture, PLAY Palm Angels is swooping into Pacsun, and they’re not just strolling in—they’re parading with a 41-piece fashion collection. Not to mention, they've snagged Avani Gregg, a powerhouse cultural influencer, to strut...

HIMS Faces Class Action: Investors Eye Leadership

Another Day, Another Lawsuit: Hims & Hers in Hot Water Here's the latest conundrum in the corporate world, folks. Hims & Hers Health, Inc. (NYSE: HIMS) is caught up in a class action lawsuit that could shake up the telehealth scene. Investors who found themselves knee-deep in losses during the class period from August 2025 to July 2026 might want to pay attention. The...

Robo.ai Surpasses $180 Million in Q2 Revenue Surge

Robo.ai's Financial Rocket Lift-off: Q2 Highlights Who would've thought a single acquisition could propel a company's revenue north of $180 million in just three months? Well, Robo.ai, with its recent grab of Quantum Core Capital (QC Capital), shattered that ceiling, showcasing what a savvy acquisition and a dash of tech wizardry can achieve. Strong Quarter, Stronger...

McLean Launches Program to Foster AI Capability

Driving AI Adoption: A Shift Towards Human-Centric Learning McLean & Company has dropped an initiative that’s like laying fresh tracks for AI inclusion in businesses. Dubbed the Human-Centric AI Program, it’s a wake-up call to organizations struggling to shift AI from a novelty to a natural part of operations. This isn’t just about fiddling with AI tools; it’s...

Cost of Living Tops Financial Worries in 2026

Financial Stress — The Silent Productivity Killer Down in the trenches of nine-to-five, it’s money that keeps stealing workers' peace of mind. The TELUS Mental Health Index shines a glaring spotlight on this, revealing that 58% of U.S. workers are most stressed by living costs. Now, that's a kicker when stacking it next to retirement or emergency savings. Those take...

Kroger's Strategic Shift: Ibbotson's Bold New Charge

Kroger Welcomes a Seasoned Retail Veteran Change often arrives with the dawn of new leadership. As Kroger takes a page from the playbook of large-scale retail transformation, they've enlisted Mark Ibbotson. Effective September 14, Ibbotson will step in as Executive Vice President and Chief Store Operations Officer. It's a roll of the dice that could either accelerate...

York Urged to Retire Research Macaques After Probe

Undercover Investigation Shakes Up York University If you thought the world of research was all about sterile labs and the pursuit of knowledge, think again. The Jane Goodall Institute (JGI), famed for championing animal welfare, has urged York University to let go of nine long-suffering rhesus macaques. Turns out, these macaques weren't exactly living their best lives....